KLI

검색

Ulsan Univ. Repository

Browsing by 저자 : Seock-Ah Im

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

가 나 다 라 마 바 사 아 자 차 카 타 파 하

또는 첫 단어:

정렬 기준:
정렬:
결과 수
저자 수

전체 결과 23건 중 1-23 번을 표시중입니다.

1 Article A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03) Dae-Won Lee ; Bhumsuk Keam ; Keun Seok Lee ; et al 2023
2 Article A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer Sherko Kuemmel ; Mario Campone ; Delphine Loirat ; et al 2022
3 Article Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial 김성배 ; Andrew M Wardley ; Arlene Chan ; et al 2020
4 Article Adding Ovarian Suppression to Tamoxifen for Premenopausal Women With Hormone Receptor-Positive Breast Cancer After Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial Soo Yeon Baek ; Woo Chul Noh ; Sei-Hyun Ahn ; et al 2023
5 Article Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16) Se Hyun Kim ; Seock-Ah Im ; Koung Jin Suh ; et al 2023
6 Article Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib 정경해 ; Jee Hyun Kim 7 ; Ji-Yeon Kim ; et al 2020
7 Article Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer Peter Schmid ; Javier Cortes ; Rebecca Dent ; et al 2022
8 Article Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer Soohyeon Lee ; Kyunghee Park ; Gun Min Kim ; et al 2022
9 Article Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study 정경해 ; Alexandra Hogea ; Andre Mattar ; et al 2021
10 Article Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study 정경해 ; Alexandra Hogea ; Andre Mattar ; et al 2021
11 Article Long-term outcomes of a phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumors of the stomach Seong-Ho Kong ; Yukinori Kurokawa ; Jeong-Hwan Yook ; et al 2023
12 Article Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial Hope S Rugo ; Seock-Ah Im ; Fatima Cardoso ; et al 2023
13 Article Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase ll Trial (KCSG-BR 15-10) 고수진 ; 정경해 ; Gun Min Kim ; et al 2020
14 Article Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial Masato Takahashi ; Javier Cortés ; Rebecca Dent ; et al 2023
15 Article Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study 김성배 ; Adam Knott ; Andreas Schneeweiss ; et al 2020
16 Article Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer Hee Kyung Ahn ; Sung Hoon Sim ; Koung Jin Suh ; et al 2022
17 Article Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES 김성배 ; Aditya Adhav ; Bulent Karabulut ; et al 2021
18 Article Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial. 김성배 ; Annabel Goodwin ; Joohyuk Sohn ; et al 2021
19 Article Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer Shanu Modi ; William Jacot ; Toshinari Yamashita ; et al 2022
20 Article Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial Sara A Hurvitz ; Roberto Hegg ; Wei-Pang Chung ; et al 2023
21 Article Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial Fabrice André ; Yeon Hee Park ; Sung-Bae Kim ; et al 2023
22 Article Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial 김성배 ; Aruna Mani ; Chiara Lambertini ; et al 2020
23 Article Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial Yen-Shen Lu ; Seock-Ah Im ; Marco Colleoni ; et al 2022

OAK Ulsan Univ. Repository는 국립중앙도서관 OAK Repository 보급사업으로 구축되었습니다.